SequelSEC

Imunon, Inc. IMNN

Pharmaceutical Preparations · CIK 0000749647 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$125.00K
Fiscal year ended 2022-12-31
Operating income
-$6.93M
Fiscal year ended 2022-12-31
Free cash flow
-$5.05M
Fiscal year ended 2022-12-31

Valuation, from the filing

Public float$21.20MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$5.40Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue53.6%90th
FCF margin-4672.9%11th
Net margin-7179.6%13th
SBC / revenue534.6%86th
R&D / revenue2346.7%84th
Operating margin-4984.3%17th
Revenue YoY growth0.0%43th
Current ratio3.66x49th

Imunon, Inc. (IMNN) reported revenue of $125.00K and net income of -$13.23M for the fiscal year ended 2022-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Imunon, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Imunon, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
Revenue$125.00K$125.00K$125.00K$125.00K$125.00K$125.00K$125.00K$125.00K$125.00K$125.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$6.93M-$6.17M-$5.98M-$5.84M-$5.49M-$5.06M-$5.07M-$5.38M-$4.79M-$4.16M
Net income-$13.23M-$6.15M-$6.04M-$10.47M-$4.22M-$5.41M-$5.45M-$5.69M-$3.01M-$8.07M
Research & development$3.00M$2.41M$3.23M$3.10M$2.99M$2.47M$2.59M$2.57M$2.81M$2.49M
Weighted-average diluted sharesUnavailableshares 7.10Mshares 6.98MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailable$-0.87$-0.87UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$4.05M$3.89M$2.88M$2.87M$2.63M$2.72M$2.60M$2.94M$2.11M$1.79M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Imunon, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
Cash & equivalents$11.49M$26.94M$26.74M$28.36M$19.59M$25.65M$26.44M$37.76M$17.16M$18.34M
Total assets$43.98M$60.53M$65.33M$64.34M$74.05M$79.47M$83.01M$73.04M$37.53M$37.27M
Current assets$36.78M$40.19M$44.91M$43.87M$51.95M$56.76M$60.31M$56.25M$18.82M$19.91M
Total liabilities$14.65M$19.18M$18.29M$18.08M$18.25M$20.13M$18.96M$18.08M$18.92M$18.62M
Current liabilities$10.04M$8.46M$6.89M$6.65M$6.77M$6.48M$5.38M$6.69M$6.75M$5.43M
Total equity incl. NCI$29.33M$41.35M$47.04M$46.27M$55.80M$59.34M$64.05M$54.96M$18.61M$18.66M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0Unavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable$1.98M$1.98M$1.98M$1.98M$1.98M
Long-term debt$5.96M$5.99M$5.95M$5.90MUnavailable$5.85M$5.76M$5.09M$5.05M$5.04M
Accounts payable$3.59M$3.37M$2.39M$3.47M$2.55M$2.62M$2.11M$2.10M$2.24M$2.17M

Cash flow

Imunon, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
Operating cash flow-$5.01M-$4.64M-$5.47M-$7.98M-$5.09M-$3.79M-$2.61M-$4.74M-$3.73M-$3.96M
Capital expenditures$44.91K$56.87K$110.13K$55.89K$25.64K$58.97K$100.40K$126.60K$5.17K$2.08K
Investing cash flow-$10.88M$4.90M-$2.49M$16.75M-$974.49K$3.01M-$17.03M-$15.12M-$5.17K$2.78M
Financing cash flow$447.31K-$64.02KUnavailableUnavailable$1-$8.32K$14.32M$40.46M$2.56M-$3.13M
Net change in cash-$15.45M$195.96K-$1.62M$8.78M-$6.06M-$788.58K-$5.32M$20.60M-$1.18M-$4.31M
Stock-based compensation$710.24K$476.28K$491.91K$994.61K$686.17K$700.62K$793.62K$1.58M$403.19K$417.48K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$218.08K$171.60K$167.96K$173.99K$160.18K$158.94K$193.21K$190.60K$169.46K$193.08K

Derived

Imunon, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
Free cash flow-$5.05M-$4.70M-$5.58M-$8.03M-$5.11M-$3.85M-$2.71M-$4.86M-$3.74M-$3.97M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-5541.4%-4939.7%-4782.6%-4673.6%-4392.7%-4049.3%-4057.1%-4306.7%-3835.1%-3327.7%
FCF margin-4042.0%-3757.7%-4466.2%-6425.9%-4091.0%-3076.1%-2170.4%-3890.8%-2989.4%-3172.7%
SBC / revenue568.2%381.0%393.5%795.7%548.9%560.5%634.9%1263.5%322.6%334.0%
Current ratio3.66x4.75x6.52x6.60x7.67x8.77x11.21x8.41x2.79x3.67x
Revenue YoY growth0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net margin-10586.1%-4918.6%-4834.3%-8379.5%-3377.0%-4328.4%-4358.7%-4551.2%-2409.7%-6457.3%
R&D / revenue2402.6%1926.9%2581.0%2476.3%2389.0%1974.5%2074.7%2057.3%2248.2%1993.4%
CapEx / revenue35.9%45.5%88.1%44.7%20.5%47.2%80.3%101.3%4.1%1.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IMNN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.